Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial
RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). 168mg curcumin, 260mg quercetin and 360IU cholecalciferol.
risk of no recovery, 33.3% lower, RR 0.67, p = 0.15, treatment 10 of 25 (40.0%), control 15 of 25 (60.0%), NNT 5.0.
|
relative CRP reduction, 39.1% better, RR 0.61, p = 0.006, treatment 25, control 25.
|
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.009, treatment 10 of 25 (40.0%), control 20 of 25 (80.0%), NNT 2.5.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Khan et al., 1 May 2022, Randomized Controlled Trial, Pakistan, peer-reviewed, 7 authors, study period 2 September, 2021 - 28 November, 2021, this trial uses multiple treatments in the treatment arm (combined with curcumin and vitamin D) - results of individual treatments may vary, trial
NCT05130671 (history).
Contact:
amjadkhan@lumhs.edu.pk.
Abstract: CLINICAL TRIAL
published: 07 June 2022
doi: 10.3389/fphar.2022.898062
Oral Co-Supplementation of
Curcumin, Quercetin, and Vitamin D3
as an Adjuvant Therapy for Mild to
Moderate Symptoms of COVID-19
—Results From a Pilot Open-Label,
Randomized Controlled Trial
Amjad Khan 1,2*, Somia Iqtadar 3, Sami Ullah Mumtaz 3, Michael Heinrich 4,
Domingo A. Pascual-Figal 5,6, Shona Livingstone 7 and Sajid Abaidullah 3
1
Edited by:
Yusof Kamisah,
Universiti Kebangaan Malaysia,
Malaysia
Reviewed by:
Ruben Manuel Luciano Colunga
Biancatelli,
Old Dominion University,
United States
Syed Mohammed Basheeruddin
Asdaq,
University of Almaarefa, Saudi Arabia
*Correspondence:
Amjad Khan
amjadkhan@lumhs.edu.pk
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 16 March 2022
Accepted: 27 April 2022
Published: 07 June 2022
Citation:
Khan A, Iqtadar S, Mumtaz SU,
Heinrich M, Pascual-Figal DA,
Livingstone S and Abaidullah S (2022)
Oral Co-Supplementation of
Curcumin, Quercetin, and Vitamin D3
as an Adjuvant Therapy for Mild to
Moderate Symptoms of COVID19—Results From a Pilot Open-Label,
Randomized Controlled Trial.
Front. Pharmacol. 13:898062.
doi: 10.3389/fphar.2022.898062
INEOS Oxford Institute for AMR Research, University of Oxford, Oxford, United Kingdom, 2Department of Biochemistry, Liaquat
University of Medical and Health Sciences, Jamshoro, Pakistan, 3Department of Medicine, King Edward Medical University,
Lahore, Pakistan, 4UCL School of Pharmacy, University of London, London, United Kingdom, 5Department of Cardiology,
University of Murcia Hospital Universitario Virgen de la Arrixaca Murcia, Murcia, Spain, 6Centro Nacional de Investigaciones
Cardiovasculares (CNIC), Madrid, Spain, 7School of medicine, University of Dundee, Dundee, United Kingdom
Background: Curcumin, quercetin, and vitamin D3 (cholecalciferol) are common natural
ingredients of human nutrition and reportedly exhibit promising anti-inflammatory,
immunomodulatory, broad-spectrum antiviral, and antioxidant activities.
Objective: The present study aimed to investigate the possible therapeutic benefits of a
single oral formulation containing supplements curcumin, quercetin, and cholecalciferol
(combinedly referred to here as CQC) as an adjuvant therapy for early-stage of
symptomatic coronavirus disease 2019 (COVID-19) in a pilot open-label, randomized
controlled trial conducted at Mayo Hospital, King Edward Medical University, Lahore,
Pakistan.
Methods: Reverse transcriptase polymerase chain reaction (RT-PCR) confirmed, mild to
moderate symptomatic COVID-19 outpatients were randomized to receive either the
standard of care (SOC) (n = 25) (control arm) or a daily oral co-supplementation of 168 mg
curcumin, 260 mg quercetin, and 9 µg (360 IU) of cholecalciferol, as two oral soft capsules
b.i.d. as an add-on to the SOC (n = 25) (CQC arm) for 14 days. The SOC includes
paracetamol with or without antibiotic (azithromycin). Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) RT-PCR test, acute symptoms, and biochemistry including
C-reactive protein (CRP), D-dimer, lactate dehydrogenase, ferritin, and complete blood
count were evaluated at baseline and follow-up day seven.
Results: Patients who received the CQC adjuvant therapy showed expedited
negativization of the SARS-CoV-2 RT-PCR test, i.e., 15 (60.0%) vs. five (20.0%) of the
control arm, p = 0.009. COVID-19- associated acute symptoms were rapidly resolved in
the..
khan4
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit